JAGX - ジャガ―・アニマル・ヘルス (Jaguar Health Inc.) ジャガ―・アニマル・ヘルス

 JAGXのチャート


 JAGXの企業情報

symbol JAGx
会社名 Jaguar Animal Health Inc (ジャガ―・アニマル・ヘルス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ジャガー・ヘルス(Jaguar Health Inc.)(旧名:Jaguar Animal Health Inc.)は天然製品医薬品会社である。同社は人の処方箋使用及び動物のためのグローバルで、新規で持続可能な派生の消化器製品の開発及び製品化に従事する。Napo Pharmaceuticals Inc.を通じて、伝統的に熱帯雨林地域で使用される植物から、世界市場向けに独自のヒト胃腸薬を開発・商品化することを行う。Mytesiは、抗レトロウィルス療法に対するヒト免疫不全ウイルスHIV /後天性免疫不全症候群(AIDS)を有する成人患者における非感染性下痢の症候性軽減のために示される抗下痢剤である。他の製品はCanalevia、Equilevia、Neonorm Calf及びNeonorm Foalを含む。   ジャガ―・アニマル・ヘルスは米国の動物用医薬品メ―カ―。ペットや生産動物用の胃腸用治療薬の開発や商品化に焦点を当てる。主な薬品候補には、犬用の水溶性下痢治療処方薬「Canalevia」がある。また、非処方箋薬として、離乳前の酪農子牛用の水溶性下痢治療薬「Neonorm」を開発。本社はサンフランシスコ。   Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
本社所在地 201 Mission Street Suite 2375 San Francisco CA 94105 USA
代表者氏名 James J. Bochnowski ジェームズJ.ボノフノキ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 415-896-5081
設立年月日 41426
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url https://jaguar.health/
nasdaq_url https://www.nasdaq.com/symbol/jagx
adr_tso
EBITDA EBITDA(百万ドル) -19.94703
終値(lastsale) 0.5701
時価総額(marketcap) 28407706.734
時価総額 時価総額(百万ドル) 14.40071
売上高 売上高(百万ドル) 4.33046
企業価値(EV) 企業価値(EV)(百万ドル) 36.40752
当期純利益 当期純利益(百万ドル) -29.79644
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Jaguar Health Inc revenues decreased 2% to $1.7M. Net loss applicable to common stockholders increased from $6.5M to $14.3M. Revenues reflect Collaboration revenue decrease of 89% to $177K. Higher net loss reflects Sales and marketing expense increase from $280K to $4.4M (expense) Interest expense increase from $336K to $1.3M (expense) General and administrative expense increase of 11% to $6.1M (expense).

 JAGXのテクニカル分析


 JAGXのニュース

   Jaguar Health CEO And Lead Ethnobotanical Researcher Explain The Decades Of Research That Made It A Leader In Plant-Based Drug Treatment  2020/10/21 11:45:52 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research and ethnopharmacological compound analysis encompassing plant species and medical traditions from indigenous communities throughout the world’s rainforest and tropical biomes, the management team at Jaguar Health (NASDAQ: JAGX ) has garnered a unique reservoir of knowledge and expertise within the biotech industry. The first fruits of this knowledge catalog yielded the company’s lead drug compound, crofelemer, which is marketed under the trade name Mytesi as a first-in-class, botanically-derived, antisecretory agent indicated for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. As the only oral plant-based prescription medicine approved under FDA botanical guidance, crofelemer represents a new paradigm in refining and applying traditional medical practices into contemporary Western healthcare.
   Jaguar Health CEO Discusses Upcoming Virtual Event Highlighting Long-Term Treatment Needs Of Cancer Patients  2020/10/15 11:29:38 Benzinga
The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. Next Tuesday, October 20th, Jaguar Health, Inc. (NASDAQ: JAGX ) will hold a live virtual webinar intended for investors that will bring together experts in patient support, medical oncology and pharmaceutical research to discuss the current landscape of supportive care for cancer patients. The first-in-kind event, Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer , aims to raise awareness in the investor community about the need for supportive care for people experiencing conditions related to chronic lower gastrointestinal tract distress — specifically, the debilitating diarrhea that often results from cancer and cancer therapy, also known as cancer therapy-related diarrhea. The event will shed light on existing diarrhea management regimens, their associated limitations and impact on patient comfort and quality-of-life and Jaguar’s related ongoing drug development program of interest to investors and the business community.
   Thinking about buying stock in Jaguar Health, Oragenics, Plug Power, FuelCell Energy, or Norwegian Cruise Line?  2020/10/06 14:45:00 PR Newswire
NEW YORK, Oct. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, OGEN, PLUG, FCEL, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Jaguar Health secures first tranche related to sale of Mytesi royalties (NASDAQ:JAGX)  2020/10/06 13:18:53 Seeking Alpha
Jaguar Health (NASDAQ:JAGX) jumps 16% premarket after it met the financial condition for the initial $5M tranche of the previously announced non-dilutive r
   Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications  2020/10/06 12:30:00 Yahoo Finance
(NASDAQ:JAGX) today announced that the company has met the financial condition for the initial $5 million tranche of the previously announced non-dilutive royalty financing transaction - which has the potential to total $16 million - involving the sale of royalty rights related to the future revenue
   Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea  2020/08/06 12:30:00 Yahoo Finance
A significant proportion of patients undergoing cancer therapy experience diarrheaSAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 / Jaguar Health, Inc.
   Jaguar Health completes IND filing for Mytesi for cancer therapy‑related diarrhea (NASDAQ:JAGX)  2020/07/06 12:56:59 Seeking Alpha
Jaguar Health (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals has completed the filing of the IND application with the FDA for crofelemer (Mytesi) for the p
   Drugmaker Questioned for Nearly Tripling Price of Potential COVID-19 Drug  2020/05/05 13:05:29 Insurance Journal
The chair of a House of Representatives committee and a fellow Democratic committee member on Monday urged Jaguar Health Inc. to reverse recent price hikes of a drug that could be used to treat side effects in COVID-19 patients and …
   Did a pharma company really triple the price of a drug capable of battling the coronavirus?  2020/04/23 19:05:14 BGR.com
A pharmaceutical company this month tripled the price of an HIV drug that could be used to help treat coronavirus symptoms. The company claims that the price increase was decided upon months before the coronavirus pandemic began. Visit BGR's homepage for more stories . There's a story making the rounds suggesting that Jaguar Health, a San Francisco-based pharmaceutical company, recently raised the price of one of its drugs by an exorbitant amount after learning it might be used to help treat coronavirus symptoms. As reported by Axios , Jaguar more than tripled the price of Mytesi, an FDA-approved drug that was initially designed to provided relief for HIV patients suffering from non-infectious diarrhea. While Mytesi typically costs about $668, Jaguar boosted the price to $2,206 earlier this month. In March, Jaguar filed a FORM 8-K with the SEC and disclosed that it asked the FDA for approval to use Mytesi "for the symptomatic relief of diarrhea and other gastrointestinal symptoms in patients with COVID-19 and for patients with COVID-19 who have diarrhea associated with certain antiviral treatments." Incidentally, Jaguar's request was not approved by the FDA.
   Drugmaker Jaguar Health triples price of antidiarrheal pill as it pursues coronavirus use  2020/04/23 09:00:57 Axios
Jaguar Health is in financial trouble and turned to a massive price hike.
   Drugmaker Questioned for Nearly Tripling Price of Potential COVID-19 Drug  2020/05/05 13:05:29 Insurance Journal
The chair of a House of Representatives committee and a fellow Democratic committee member on Monday urged Jaguar Health Inc. to reverse recent price hikes of a drug that could be used to treat side effects in COVID-19 patients and …
   Did a pharma company really triple the price of a drug capable of battling the coronavirus?  2020/04/23 19:05:14 BGR.com
A pharmaceutical company this month tripled the price of an HIV drug that could be used to help treat coronavirus symptoms. The company claims that the price increase was decided upon months before the coronavirus pandemic began. Visit BGR's homepage for more stories . There's a story making the rounds suggesting that Jaguar Health, a San Francisco-based pharmaceutical company, recently raised the price of one of its drugs by an exorbitant amount after learning it might be used to help treat coronavirus symptoms. As reported by Axios , Jaguar more than tripled the price of Mytesi, an FDA-approved drug that was initially designed to provided relief for HIV patients suffering from non-infectious diarrhea. While Mytesi typically costs about $668, Jaguar boosted the price to $2,206 earlier this month. In March, Jaguar filed a FORM 8-K with the SEC and disclosed that it asked the FDA for approval to use Mytesi "for the symptomatic relief of diarrhea and other gastrointestinal symptoms in patients with COVID-19 and for patients with COVID-19 who have diarrhea associated with certain antiviral treatments." Incidentally, Jaguar's request was not approved by the FDA.
   Drugmaker Jaguar Health triples price of antidiarrheal pill as it pursues coronavirus use  2020/04/23 09:00:57 Axios
Jaguar Health is in financial trouble and turned to a massive price hike.
   Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMT  2020/04/07 15:00:08 Yahoo Finance
Q4 2019 Jaguar Health Inc Earnings Call
   The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment  2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ジャガ―・アニマル・ヘルス JAGX Jaguar Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)